

Roger Abounader

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9132673/publications.pdf>

Version: 2024-02-01

74
papers

5,519
citations

76326

40
h-index

82547

72
g-index

103
all docs

103
docs citations

103
times ranked

7842
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA 3928 Suppresses Glioblastoma through Downregulation of Several Oncogenes and Upregulation of p53. International Journal of Molecular Sciences, 2022, 23, 3930.	4.1	8
2	Transcribed Ultraconserved Regions in Cancer. Cells, 2022, 11, 1684.	4.1	6
3	MicroRNAs: Key Regulators in Lung Cancer. MicroRNA (Sharjah, United Arab Emirates), 2021, 10, 109-122.	1.2	6
4	A new class of radiosensitizers for glioblastoma. Oncotarget, 2021, 12, 1199-1200.	1.8	0
5	The blood-brain barrier limits the therapeutic efficacy of antibody-drug conjugates in glioblastoma. Neuro-Oncology, 2021, 23, 1993-1994.	1.2	4
6	The tumor-suppressive long noncoding RNA DRAIC inhibits protein translation and induces autophagy by activating AMPK. Journal of Cell Science, 2021, 134, .	2.0	18
7	A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma. Nature Communications, 2020, 11, 3457.	12.8	35
8	HGF/MET Signaling in Malignant Brain Tumors. International Journal of Molecular Sciences, 2020, 21, 7546.	4.1	21
9	Activities of Some Medicinal Plants on the Proliferation and Invasion of Brain Tumor Cell Lines. Advances in Pharmacological and Pharmaceutical Sciences, 2020, 2020, 1-7.	1.3	6
10	Gene expression in mouse muscle over time after nickel pellet implantation. Metallomics, 2020, 12, 528-538.	2.4	5
11	CSIG-01. IDENTIFICATION OF PATHOGENESIS-RELEVANT microRNAs IN BRAIN METASTASIS. Neuro-Oncology, 2020, 22, ii27-ii27.	1.2	0
12	MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway. Journal of Neuro-Oncology, 2019, 145, 23-34.	2.9	33
13	Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. Cancer Research, 2019, 79, 5218-5232.	0.9	57
14	Ethanol Extract of <i>Securidaca longipedunculata</i> Induces Apoptosis in Brain Tumor (U87) Cells. BioMed Research International, 2019, 2019, 1-5.	1.9	11
15	Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clinical Cancer Research, 2019, 25, 663-673.	7.0	35
16	A new practical and versatile mouse model of proneural glioblastoma. Neuro-Oncology, 2018, 20, 299-301.	1.2	2
17	p53 and NF1 loss plays distinct but complementary roles in glioma initiation and progression. Glia, 2018, 66, 999-1015.	4.9	19
18	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro-Oncology, 2018, 20, 192-202.	1.2	52

#	ARTICLE	IF	CITATIONS
19	Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2018, 1861, 983-995.	1.9	21
20	The p53 Pathway in Glioblastoma. <i>Cancers</i> , 2018, 10, 297.	3.7	232
21	Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 4360-4369.	0.9	46
22	Targetable T-type Calcium Channels Drive Glioblastoma. <i>Cancer Research</i> , 2017, 77, 3479-3490.	0.9	79
23	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. <i>Clinical Cancer Research</i> , 2017, 23, 6958-6968.	7.0	74
24	Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. <i>Cancers</i> , 2017, 9, 87.	3.7	53
25	Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002192.	8.4	71
26	370â€fMagnetic Resonance-Guided Focused Ultrasound Delivery of Polymeric Brain-Penetrating Nanoparticle MicroRNA Conjugates in Glioblastoma. <i>Neurosurgery</i> , 2016, 63, 210.	1.1	22
27	Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. <i>PLoS ONE</i> , 2015, 10, e0134426.	2.5	30
28	Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1078-1085.	1.2	28
29	Targeting MET for glioma therapy. <i>Neurosurgical Focus</i> , 2014, 37, E10.	2.3	45
30	microRNA-148a Is a Prognostic oncomiR That Targets MIG6 and BIM to Regulate EGFR and Apoptosis in Glioblastoma. <i>Cancer Research</i> , 2014, 74, 1541-1553.	0.9	106
31	MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET. <i>PLoS ONE</i> , 2014, 9, e91546.	2.5	80
32	A New lncRNA, APTR, Associates with and Represses the CDKN1A/p21 Promoter by Recruiting Polycomb Proteins. <i>PLoS ONE</i> , 2014, 9, e95216.	2.5	76
33	Novel Anti-Apoptotic MicroRNAs 582-5p and 363 Promote Human Glioblastoma Stem Cell Survival via Direct Inhibition of Caspase 3, Caspase 9, and Bim. <i>PLoS ONE</i> , 2014, 9, e96239.	2.5	95
34	A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy. <i>Neoplasia</i> , 2013, 15, 952-965.	5.3	46
35	Diacylglycerol Kinase Î± Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers. <i>Cancer Discovery</i> , 2013, 3, 782-797.	9.4	93
36	The p53â€fmicroRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses. <i>Medical Hypotheses</i> , 2013, 81, 62-67.	1.5	7

#	ARTICLE	IF	CITATIONS
37	Oncogenic effects of miR-10b in glioblastoma stem cells. <i>Journal of Neuro-Oncology</i> , 2013, 112, 153-163.	2.9	151
38	A miR-297/hypoxia/DGK-1 \pm axis regulating glioblastoma survival. <i>Neuro-Oncology</i> , 2013, 15, 1652-1663.	1.2	42
39	Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition. <i>Clinical Cancer Research</i> , 2013, 19, 1433-1444.	7.0	29
40	microRNA-34a promotes DNA damage and mitotic catastrophe. <i>Cell Cycle</i> , 2013, 12, 3500-3511.	2.6	45
41	Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 288-297.	4.1	20
42	The role of microRNAs in glioma initiation and progression. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 700.	3.0	94
43	The roles of viruses in brain tumor initiation and oncomodulation. <i>Journal of Neuro-Oncology</i> , 2011, 105, 451-466.	2.9	52
44	When tumor cells make blood vessels: implications for glioblastoma therapy. <i>Future Oncology</i> , 2011, 7, 841-843.	2.4	5
45	Insight into the role of microRNAs in brain tumors (Review). <i>International Journal of Oncology</i> , 2011, 40, 605-24.	3.3	10
46	An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 28-35.	1.7	50
47	microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. <i>Cell Cycle</i> , 2010, 9, 1031-1036.	2.6	289
48	XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 112-21.	0.7	49
49	The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors. <i>Journal of Neuroscience</i> , 2009, 29, 15161-15168.	3.6	211
50	MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes. <i>Cancer Research</i> , 2009, 69, 7569-7576.	0.9	566
51	Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 376-385.	4.1	46
52	Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 235-245.	2.4	43
53	Signaling pathways in medulloblastoma. <i>Journal of Cellular Physiology</i> , 2008, 217, 577-583.	4.1	72
54	Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. <i>Laboratory Investigation</i> , 2008, 88, 98-111.	3.7	61

#	ARTICLE	IF	CITATIONS
55	PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations. <i>Cancer Research</i> , 2008, 68, 1723-1731.	0.9	92
56	Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor. <i>Molecular Cancer Research</i> , 2008, 6, 139-150.	3.4	85
57	microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma. <i>Cancer Research</i> , 2008, 68, 3566-3572.	0.9	705
58	Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. <i>Laboratory Investigation</i> , 2005, 85, 1457-1470.	3.7	102
59	Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. <i>Neuro-Oncology</i> , 2005, 7, 436-451.	1.2	269
60	The Scatter Factor/Hepatocyte Growth Factor: c-Met Pathway in Human Embryonal Central Nervous System Tumor Malignancy. <i>Cancer Research</i> , 2005, 65, 9355-9362.	0.9	103
61	Targeting the c-Met Pathway Potentiates Glioblastoma Responses to $\hat{3}$ -Radiation. <i>Clinical Cancer Research</i> , 2005, 11, 4479-4486.	7.0	117
62	Design and Expression of Chimeric U1/Ribozyme Transgenes. , 2004, 252, 209-220.		7
63	Regulation of c-Met-dependent gene expression by PTEN. <i>Oncogene</i> , 2004, 23, 9173-9182.	5.9	51
64	CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. <i>Glia</i> , 2004, 45, 297-306.	4.9	36
65	Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. <i>Cancer Research</i> , 2003, 63, 2990-6.	0.9	55
66	Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. <i>Clinical Cancer Research</i> , 2003, 9, 4274-81.	7.0	38
67	In vivo targeting of SF/HGF and c-Met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. <i>FASEB Journal</i> , 2002, 16, 1-16.	0.5	159
68	BIIIE0246, a potent and highly selective non-peptide neuropeptide Y ₂ receptor antagonist. <i>British Journal of Pharmacology</i> , 2000, 129, 1075-1088.	5.4	111
69	Glioma Inhibition by HGF/NK2, an Antagonist of Scatter Factor/Hepatocyte Growth Factor. <i>Biochemical and Biophysical Research Communications</i> , 2000, 273, 287-293.	2.1	23
70	Expression of Neuropeptide Y Receptors mRNA and Protein in Human Brain Vessels and Cerebromicrovascular Cells in Culture. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 155-163.	4.3	49
71	Scatter factor/hepatocyte growth factor gene transfer increases rat blood-brain glioma barrier permeability. <i>Brain Research</i> , 1999, 833, 173-180.	2.2	16
72	Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y ₁ antagonist BIBP 3226. <i>British Journal of Pharmacology</i> , 1995, 116, 2245-2250.	5.4	82

#	ARTICLE	IF	CITATIONS
73	Patterns of Capillary Plasma Perfusion in Brains of Conscious Rats During Normocapnia and Hypercapnia. <i>Circulation Research</i> , 1995, 76, 120-126.	4.5	38
74	Noncoding RNAs in Glioblastoma. , 0, , 95-130.		19